Valeant CEO 'delighted' by Paulson's Allergan stake

Thu Jun 26, 2014 1:37pm EDT

J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec May 20, 2014. REUTERS/Christinne Muschi

J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec May 20, 2014.

Credit: Reuters/Christinne Muschi

Related Topics

(Reuters) - Valeant Pharmaceuticals Inc's (VRX.TO) chief executive said on Thursday he is "delighted" that hedge fund Paulson & Co has amassed a large stake in takeover target Allergan Inc (AGN.N), and that he believes Valeant will garner enough support to trigger a special meeting of Allergan's board.

Reuters reported exclusively on Wednesday that Paulson had built a stake in Allergan of more than 6 million shares and supports a deal between the Botox maker and Valeant.

Paulson's shares, along with stock owned by Valeant ally Pershing Square Capital Management, give the company "a nice starting point" toward reaching at least 25 percent support of Allergan shares needed to call the special meeting that could replace most of Allergan's board, Valeant Chief Executive Michael Pearson said.

"We do believe we'll get the 25 percent and the majority we need to get this deal consummated," Pearson said on Canada's BNN TV.

Allergan has rejected Valeant's hostile $52 billion bid and refused to negotiate.

(Reporting by Rod Nickel in Winnipeg, Manitoba; editing by Matthew Lewis)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
dragonass wrote:
The best way to increase sales of xeomin and dysport will be for Valeant to buy Allergan which will ruin the botox business by driving physicians away. Sadly, Allergan has a good R&D pipeline which will be cast away since Valeant (despite words to the otherwise) has so far thrown out promising R&D projects or even whole departments when it has bought other companies. At some point Valeant will collapse under its own weight since you can only acquire drugs for so long before the pipeline runs dry, and since they have gutted any significant R&D from all of their other companies it will have very little future.

Jun 26, 2014 1:56pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.